These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Kakavand H; Vilain RE; Wilmott JS; Burke H; Yearley JH; Thompson JF; Hersey P; Long GV; Scolyer RA Mod Pathol; 2015 Dec; 28(12):1535-44. PubMed ID: 26403784 [TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival. Alessi C; Scapulatempo Neto C; Viana CR; Vazquez VL Melanoma Res; 2017 Dec; 27(6):565-572. PubMed ID: 28984690 [TBL] [Abstract][Full Text] [Related]
4. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Spanknebel K; Coit DG; Bieligk SC; Gonen M; Rosai J; Klimstra DS Am J Surg Pathol; 2005 Mar; 29(3):305-17. PubMed ID: 15725798 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Eggermont AM Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171 [TBL] [Abstract][Full Text] [Related]
6. Nodular primary cutaneous melanoma is associated with PD-L1 expression. Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795 [TBL] [Abstract][Full Text] [Related]
7. Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Goto Y; Ferrone S; Arigami T; Kitago M; Tanemura A; Sunami E; Nguyen SL; Turner RR; Morton DL; Hoon DS Clin Cancer Res; 2008 Jun; 14(11):3401-7. PubMed ID: 18519770 [TBL] [Abstract][Full Text] [Related]
8. Frequency of Expression of PD-1 and PD-L1 In Head And Neck Squamous Cell Carcinoma And their Association With Nodal Metastasis: A Cross-Sectional Study. Malik IS; Asif M; Bashir N; Ara N; Rashid F; Din HU; Malik NS; Bashir A Asian Pac J Cancer Prev; 2022 Feb; 23(2):467-473. PubMed ID: 35225458 [TBL] [Abstract][Full Text] [Related]
9. Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, Morales-Betanzos CA; Lee H; Gonzalez Ericsson PI; Balko JM; Johnson DB; Zimmerman LJ; Liebler DC Mol Cell Proteomics; 2017 Oct; 16(10):1705-1717. PubMed ID: 28546465 [TBL] [Abstract][Full Text] [Related]
10. Sentinel node identification by scintigraphic methods in cutaneous melanoma. Dias Moreira R; Altino de Almeida S; Maliska Guimarães CM; Resende JF; Gutfilen B; Barbosa da Fonseca LM J Exp Clin Cancer Res; 2005 Jun; 24(2):181-5. PubMed ID: 16110749 [TBL] [Abstract][Full Text] [Related]
11. Lymphatic flow is mostly preserved after sentinel lymph node biopsy in primary cutaneous malignant melanoma. Yokota K; Sawada M; Matsumoto T; Hasegawa Y; Kono M; Akiyama M J Dermatol Sci; 2015 May; 78(2):101-7. PubMed ID: 25771166 [TBL] [Abstract][Full Text] [Related]
12. Diversity of stage III melanoma in the era of sentinel lymph node biopsy. Egger ME; Callender GG; McMasters KM; Ross MI; Martin RC; Edwards MJ; Urist MM; Noyes RD; Sussman JJ; Reintgen DS; Stromberg AJ; Scoggins CR Ann Surg Oncol; 2013 Mar; 20(3):956-63. PubMed ID: 23064795 [TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph nodes containing very small (<0.1 mm) deposits of metastatic melanoma cannot be safely regarded as tumor-negative. Murali R; DeSilva C; McCarthy SW; Thompson JF; Scolyer RA Ann Surg Oncol; 2012 Apr; 19(4):1089-99. PubMed ID: 22271204 [TBL] [Abstract][Full Text] [Related]
14. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma. Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039 [TBL] [Abstract][Full Text] [Related]
15. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654 [TBL] [Abstract][Full Text] [Related]
17. Small and Isolated Immunohistochemistry-positive Cells in Melanoma Sentinel Lymph Nodes Are Associated With Disease-specific and Recurrence-free Survival Comparable to that of Sentinel Lymph Nodes Negative for Melanoma. LeBlanc RE; Barton DT; Li Z; Angeles CV; Ernstoff MS; Bagley E; Wimmer D; Wong SL; Barth RJ; Shirai K; Yan S Am J Surg Pathol; 2019 Jun; 43(6):755-765. PubMed ID: 31091203 [TBL] [Abstract][Full Text] [Related]
18. PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas. Pérottet J; Le Goff E; Legoupil D; Quéré G; Schick U; Marcorelles P; Uguen A Appl Immunohistochem Mol Morphol; 2020 Feb; 28(2):161-165. PubMed ID: 32044885 [TBL] [Abstract][Full Text] [Related]
19. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients. Fujisawa Y; Otsuka F; Melanoma Res; 2012 Oct; 22(5):362-7. PubMed ID: 22713797 [TBL] [Abstract][Full Text] [Related]
20. Lymphangiogenesis and its correlation with the VEGF expression and the sentinel lymph node in cutaneous melanomas. Buzrla P; Dvorackova J; Motyka O Biomed Res Int; 2014; 2014():372979. PubMed ID: 25089267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]